Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00297895 · ClinicalTrials.gov registry record · NA

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

A NA study, sponsored by Saint John's Cancer Institute.

Completed
Registry status
NA
Development phase
1,939
Enrollment target

NCT00297895 is a NA study that has completed, run by Saint John's Cancer Institute. The registered enrollment target is 1,939 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00297895, a NA study, has completed, sponsored by Saint John's Cancer Institute.

COMPLETED
Registry status
NA
Development phase
1,939 participants
Enrollment target

Study Summary

Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.

Interventions

  • PROCEDURE Completion Lymphadenectomy
  • PROCEDURE Monitoring with nodal ultrasound

Trial Details

FieldValue
Enrollment Target 1,939 participants
Start Date 2004-09-30
Est. Completion 2019-09-30
Phase NA

Sponsor

Saint John's Cancer Institute

19 total trials

What the Registry Record Tells You About NCT00297895

The ClinicalTrials.gov registry entry for NCT00297895 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,939 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Completion Lymphadenectomy is the first listed.

NCT00297895 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00297895 about?

NCT00297895 is a clinical study titled "Multicenter Selective Lymphadenectomy Trial II (MSLT-II)". Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed...

What is the current status of trial NCT00297895?

This trial is currently completed. It is a NA study. The enrollment target is 1,939 participants. The study started on 2004-09-30. Estimated completion is 2019-09-30.

What interventions are being tested in trial NCT00297895?

The interventions under investigation include: Completion Lymphadenectomy (PROCEDURE), Monitoring with nodal ultrasound (PROCEDURE).

Who is sponsoring clinical trial NCT00297895?

This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.